Daily News

Tesla’s total deliveries came in at 480,126 units in the second quarter, beating Wall Street expectations of about 406,600 vehicles.

Sable Offshore priced its offering of 32.47 million shares at $3.08 per share, matching Tuesday's closing price.

Concentrix Corporation, Farmmi, and Hertz Global have declined between 48% and 80% so far in 2026.

SK Hynix filed a registration statement with the Securities and Exchange Commission, a step toward listing on the Nasdaq Global Select Market under the ticker symbol SKHY.

B. Riley said Pagaya’s current valuation of about 7.9 times its forward earnings estimate of $2.10 per share is well below comparable fintech companies.

Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.

Federal disclosures revealed that President Donald Trump acquired between $1 million and $5 million in shares in February, just weeks before ICE reportedly issued a $220 million request to purchase tasers.

Surf Air Mobility and Palantir are set to dedicate additional engineering and go-to-market resources to accelerate SurfOS development.

The U.S. Food and Drug Administration will hold an advisory committee meeting to review the biologics license application for Capricor’s DMD therapy on July 29

Keybanc said Nike’s outlook is further clouded by growing uncertainty around operations in China and EMEA, as well as management transition.

SLS short interest climbed to nearly 33% of the float as of June 15, compared to 28.4% at the beginning of the year.

Micron’s stunning third-quarter results sparked a rally that briefly pushed its market capitalization to nearly $1.42 trillion.

Hertz priced its previously announced $100 million share offering and upsized its $300 million exchangeable notes offering.

Sealsq and Wisekey’s special-purpose vehicle, Quantisimo, signed an LOI with GigCapital8 to explore the establishment of a Nasdaq-listed quantum technology platform.

Stifel said the shift in BlackBerry’s business model could support stronger margins and improved free cash flow generation over time, potentially leading to guidance increases.

Atlantic International’s recently acquired unit secured a $52 million government contract in the Netherlands.

Zevra Therapeutics shares saw a series of positive brokerage actions after the company asked the U.S. Food and Drug Administration to add a new patent for its Miplyffa drug to the Orange Book.

Tango Therapeutics’ experimental cancer drug Vopimetostat, in combination with Daraxonrasib, achieved a 92% objective response rate in patients with advanced pancreatic cancer.

Bernstein downgraded the stocks, citing headwinds from surging oil prices, the GLP-1 trend, and rising inflation.

Rallybio announced a merger agreement with Avenzo Therapeutics to create a publicly traded, oncology-focused biotechnology company.

Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy RP2.

Barclays said Ford’s opportunity in the energy storage market should be weighed against potential execution and scaling challenges.

CorMedix reported strong Q1 results, with revenue coming at $127.4 million, far exceeding Wall Street’s guidance of around $105 million, according to Fiscal.ai data.

Eli Lilly made several multi-billion dollar acquisitions in 2026, with a strong focus on strengthening its oncology pipeline.

Aspire Biopharma’s board approved a share repurchase program of up to $5 million, which will be funded from existing cash.

Evercore ISI raised CoreWeave’s price target to $150 from $120 and maintained an ‘Outperform’ rating, after the company secured a $6 billion deal with Jane Street for the use of its AI cloud services.

After a sharp selloff last week, NOW stock gained 6% on Monday, following a bullish note by Bernstein.

Trading of Actelis’ shares is expected to be suspended on April 10, after the company failed to meet Nasdaq’s minimum bid price requirement.

Novo said the European Medicines Agency approved transporting its blockbuster Wegovy injection at up to 30°C for up to 48 hours.

Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.

Applied Optoelectronics has secured three major orders from hyperscale customers over the past month.

Huachen AI Parking Management’s shares have been trending lower this year, with the stock struggling to comply with Nasdaq’s $1 minimum bid requirement.

The company unveiled a platform designed to digitally track physical materials across the entire supply chain.

According to an SEC filing dated April 2, Agriculture Investment Group became the controlling shareholder of Moolec Science.

Maxson, a former executive vice president and group CFO of Schneider Electric, will replace Doug Kehring.

Shares of the company have surged after a Chinese court ruled in its favor in a patent infringement case against Apple last week.

Profusa announced plans to acquire the PanOmics diagnostic platform from BioInsights.

The study also showed discontinuation rates due to gastrointestinal events were roughly 14 times higher with orforglipron.

Following a weak February due to an extended Lunar New Year holiday, Nio, Xpeng, and Li Auto reported a strong sequential increase in vehicle deliveries for March.

The company regained compliance after the stock closed at or above $1 for at least 20 consecutive business days.

The company announced a 1-for-20 reverse stock split, effective April 6, 2026.

Novo said patients can save up to $600 per year on Wegovy pills and up to $1,200 per year on Wegovy injections with a 12-month subscription.

The biotech firm announced a deal to acquire a potential treatment for a kidney disease and secured $40 million through a private placement.

The biotech company signed a binding agreement with Allucent to support a planned Phase 2 trial to treat multiple sclerosis.

Wave Life Sciences’ interim data from the Phase 1 trial of its obesity drug showed 1% reduction in total body weight in six months, a figure that left retail investors disappointed.

The biotech firm’s Phase 1/2 trial data for its gene-editing therapy BEAM-302 showed marked improvement in patients with AAT deficiency.

The AI-based entertainment company terminated its share sale agreement with Alliance Global Partners after selling around 5.9 million shares under the deal.

AEye caught retail attention after reporting a 110% increase in fourth-quarter revenue and joining NVIDIA's Halos AI Systems Inspection Lab to boost its lidar solutions.

Teladoc Health drew investor interest following a couple of bullish brokerage actions after peer Talkspace signed an acquisition agreement with Universal Health Services a day earlier.

The Chinese EV maker reported a 76% increase in fourth-quarter revenue, beating Wall Street estimates, according to Fiscal.ai data.